Jun 2026 (Q2 FY26) — Aug 4, 2026
Stevanato Group Q2 FY26 — Strong Biologics & HVS Growth, Alina Pen Approval
Read the full callStevanato Group (STVN) earnings
- Jun 2026 (Q2 FY26)
- Dec 2025
Stevanato Group earnings: last reported Tue, 4 Aug 2026, for the quarter ended Jun 2026.
Guidance
What management said, and what became of it
8 of 11 judged targets kept · 29 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Fiscal 2026 adjusted EBITDA guidance | EUR 331.8 million to EUR 346.9 million | Dec 2025 | the divestiture, while small, is expected to be accretive to margins at the central point of our guide, and we now expect adjusted EBITDA between EUR 335 million to EUR 345.2 million | Revised Up |
| Engineering segment return to historical revenue/margin performance | step-by-step improvement to be back to 'original' (historical) performance more and more in 2027 | Jun 2026 | our goal is really to have, quarter-by-quarter, some improvement in terms of revenue and marginality in order to be back to original number more and more in 2027 | New |
3 of Stevanato Group S.p.A.'s 40 targets were missed. See which ones, and which are quietly gone. The 2 above are the free sample; 38 more targets are in the full ledger.
Claimed
- Revenue grew 8% year-over-year to EUR 302 million, both reported and at constant currency.
- High-value solutions (HVS) revenue increased 16% and represented 45% of total company revenue.
- Adjusted EBITDA increased 21% to EUR 78.7 million, with adjusted EBITDA margin expanding 280 basis points to 26%.
- Biopharmaceutical and Diagnostic Solutions (BDS) segment revenue increased 9% to EUR 266.2 million.
- Engineering segment gross profit margin improved by 540 basis points to 12%, and operating profit margin increased 370 basis points to 2.9%.
Qualified
- Engineering segment revenue decreased 2% to EUR 35.8 million due to lower sales in pharma visual inspection and glass converting.
- One-time expenses of EUR 12.2 million were recorded in connection with the sale of Balda C. Brewer.
- The company reported negative free cash flow of EUR 32 million for the second quarter of 2026.
- The full-year 2026 effective tax rate is expected to be higher at approximately 28.2%, due to the absence of a prior-year tax incentive and no tax benefit on the divestiture.
Price
$19.02 +0.63% · +$0.12
Performance −22.2% 1Y
1Y: $24.44 on 17 Oct 2025 → $19.02. High $27.61 (23 Oct 2025), low $13.43 (27 Mar 2026).
- Previous close
- $18.9
- 52-week range
- $13.43 – $27.61
- One year
- −26.45%
Overview
- Symbol
- STVN
- Sector
- Health Care
- Industry
- Surgical & Medical Instruments & Apparatus
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
8 of 11 judged targets kept · 29 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Fiscal 2026 adjusted EBITDA guidance | EUR 331.8 million to EUR 346.9 million | Dec 2025 | the divestiture, while small, is expected to be accretive to margins at the central point of our guide, and we now expect adjusted EBITDA between EUR 335 million to EUR 345.2 million | Revised Up |
| Engineering segment return to historical revenue/margin performance | step-by-step improvement to be back to 'original' (historical) performance more and more in 2027 | Jun 2026 | our goal is really to have, quarter-by-quarter, some improvement in terms of revenue and marginality in order to be back to original number more and more in 2027 | New |
Claimed
- Revenue grew 8% year-over-year to EUR 302 million, both reported and at constant currency.
- High-value solutions (HVS) revenue increased 16% and represented 45% of total company revenue.
- Adjusted EBITDA increased 21% to EUR 78.7 million, with adjusted EBITDA margin expanding 280 basis points to 26%.
- Biopharmaceutical and Diagnostic Solutions (BDS) segment revenue increased 9% to EUR 266.2 million.
- Engineering segment gross profit margin improved by 540 basis points to 12%, and operating profit margin increased 370 basis points to 2.9%.
Qualified
- Engineering segment revenue decreased 2% to EUR 35.8 million due to lower sales in pharma visual inspection and glass converting.
- One-time expenses of EUR 12.2 million were recorded in connection with the sale of Balda C. Brewer.
- The company reported negative free cash flow of EUR 32 million for the second quarter of 2026.
- The full-year 2026 effective tax rate is expected to be higher at approximately 28.2%, due to the absence of a prior-year tax incentive and no tax benefit on the divestiture.
The full ledger
Open Stevanato Group S.p.A.’s full ledger
A free account opens 5 company ledgers a month. All 40 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — May 7, 2026
Stevanato Group Q1 FY26 — Strong BDS Growth Driven by GLP-1s and Capacity Expansion
Read the full callDec 2025 (Q4 FY25) — Mar 4, 2026
Stevanato Group Q4 FY25 — Strong High-Value Solutions Growth and GLP-1 Tailwinds
Read the full callEvery analysed call
Stevanato Group earnings calls (STVN)
Financials
What the filings say
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total liabilities | — | 807 | 654 | 708 | 1,038 | 960 | 1,243 |
| Fixed assets | — | 385 | 445 | 684 | 1,136 | 1,297 | 1,635 |
| Total assets | — | 1,188 | 1,607 | 1,770 | 2,289 | 2,419 | 2,989 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operations | 48 | 191 | 151 | 110 | 116 | 162 | 336 |
| Cash from investing | -84 | -118 | -109 | -259 | -465 | -322 | -321 |
| Cash from financing | 47 | -33 | 289 | -48 | 175 | 190 | 26 |
| Capital expenditure | -76 | -110 | -122 | -251 | -479 | -314 | -310 |
| Free cash flow | -29 | 81 | 29 | -140 | -362 | -153 | 26 |
Insider filings
19 filings between Jun 9, 2026 and Sep 28, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$561.8K
8 sales by 8 insiders
Compensation
not trading decisions- 9
- Award — granted as compensation
- 2
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Stocchi Mauro | — | $293.5K | Sep 28, 2026 |
| Dal Lago Marco | — | $84.6K | Aug 7, 2026 |
| Magistretti Elisabetta | — | $41.1K | Aug 7, 2026 |
| Santel Luciano | — | $40.6K | Aug 7, 2026 |
| Balachandran Madhavan | — | $25.5K | Jun 15, 2026 |
| Flynn Karen | — | $25.5K | Jun 15, 2026 |
| FEDERICI WILLIAM J | — | $25.5K | Jun 15, 2026 |
| MOREL DONALD E JR | — | $25.5K | Jun 15, 2026 |
Latest filings (19)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 28, 2026 | Stocchi Mauro See Remarks | Sale | 13,649 | $293.5K |
| Aug 7, 2026 | Dal Lago Marco Chief Financial Officer | Sale | 4,209 | $84.6K |
| Aug 7, 2026 | Santel Luciano Director | Sale | 2,023 | $40.6K |
| Aug 7, 2026 | Magistretti Elisabetta Director | Sale | 2,045 | $41.1K |
| Jun 15, 2026 | MOREL DONALD E JR Director | Sale | 1,493 | $25.5K |
| Jun 15, 2026 | Flynn Karen Director | Sale | 1,493 | $25.5K |
| Jun 15, 2026 | Balachandran Madhavan Director | Sale | 1,493 | $25.5K |
| Jun 15, 2026 | FEDERICI WILLIAM J Director | Sale | 1,493 | $25.5K |
| Jun 12, 2026 | MOREL DONALD E JR Director | Award | 4,975 | $0 |
| Jun 12, 2026 | LIN SUE-JEAN Director | Award | 4,975 | $0 |
| Jun 12, 2026 | Flynn Karen Director | Award | 4,975 | $0 |
| Jun 12, 2026 | Balachandran Madhavan Director | Award | 4,975 | $0 |
| Jun 12, 2026 | Santel Luciano Director | Award | 4,975 | $0 |
| Jun 12, 2026 | Magistretti Elisabetta Director | Award | 4,975 | $0 |
| Jun 12, 2026 | FEDERICI WILLIAM J Director | Award | 4,975 | $0 |
| Jun 12, 2026 | Dal Lago Marco Chief Financial Officer | Award | 2,356 | $0 |
| Jun 12, 2026 | Dal Lago Marco Chief Financial Officer | Option exercise | 7,997 | $0 |
| Jun 9, 2026 | Stocchi Mauro See Remarks | Option exercise | 6,586 | $0 |
| Jun 9, 2026 | Stocchi Mauro See Remarks | Award | 2,101 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Stevanato Group S.p.A.
Free account. Everything above stays public.
Write why you follow Stevanato Group S.p.A. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading